Dermata Therapeutics shares surge 29.57% after-hours after $12.4M private placement to fund OTC acne kit launch.

Dermata Therapeutics (DRMA) surged 29.57% in after-hours trading, driven by a $12.4 million private placement led by H.C. Wainwright & Co. to fund its OTC acne kit launch and R&D. The offering included 2.02 million shares and warrants exercisable at $2.04, with insider participation signaling confidence. The capital will accelerate pre-launch activities for a mid-2026 acne kit and strategic acquisitions, aligning with the company’s pivot to OTC dermatologic solutions. Additional bullish factors included positive FDA designations and trial results, as well as a rebranding effort blending traditional wisdom with modern science to attract consumers. These developments collectively fueled investor optimism about Dermata’s growth prospects and market expansion.